← All trials
NCT00000136
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 1990
- Primary completion
- Oct 1, 1991
- Completion date
- Oct 1, 1991
- First posted
- —
- Last posted
- —
- Enrollment
- 234
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Johns Hopkins UniversityLead sponsor
- University of MiamiCollaborator
- New York UniversityCollaborator
- Johns Hopkins UniversityOverall official - principal investigator
- National Eye Institute (NEI)Collaborator
- Johns Hopkins UniversityCollaborator
- Northwestern UniversityCollaborator
- University of California, Los AngelesCollaborator
- University of California, San DiegoCollaborator
- University of California, San FranciscoCollaborator
- Cornell UniversityCollaborator
- University of MassachusettsCollaborator
- University of WisconsinCollaborator
- Baylor UniversityCollaborator
- Louisiana State UniversityCollaborator
- New York Presbyterian HospitalCollaborator
- Icahn School of Medicine at Mount SinaiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.